Considering the reductions in the reimbursed drug prices, and relevant medical insurance reimbursement factors, patients’ financial burden will likely be reduced by over RMB 40 billion in the next two years. Negotiation status in the past five years (source: NHSA website): Average ...
the reimbursed products could not come close to their prices in other countries, and a substantial level of discount appears to be necessary to be included in 2022 NRDL, for example, a 94% price cut in the negotiation.
The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysisdoi:10.3389/fpubh.2024.1381786Zhaohui QinMeng HeHuangying ShenSha LiuShuo XuLijiang Chen
路透社记者：今天，美国政府发布的报告称，中国直接支持国内生产违法毒品芬太尼。请问你对此有何评论？ Reuters: According to a report released by the US government today, China has directly supported its domestic production of illicit drug fentanyl. What’s your comment? 林剑：我不了解你提到的具体情况。
In addition to expanding the drug catalog, the government has worked to lower prices through bulk procurement and price negotiation programs. The latest government-led bulk procurement of medicines was just finalized in December. This marked the 10th batch of procurement jointly launched by the NHSA...
According to NHSA, 117 off-list drugs took part in the negotiation and bidding process this year, with 89 successfully negotiated, achieving a success rate of 76% and an average price reduction of 63%. 1. Highlights of the 2024 NRDL Prioritization of New Drug The 2024 NRDL inclusion priorit...
inconsistency of rights has led to the determination of many drug prices not based on the ability to pay for medical insurance. It was not until the establishment of the National Healthcare Security Administration t...
In September 2019, the “4 + 7” centralized procurement pilot program was expanded nationwide aiming at reducing drug prices by means of volume-based procurement and using accredited generic drugs for branded drug substitutes. Given the current uncertain effect of the policy outside pilot areas...
2021 marks the fourth consecutive year that the National Healthcare Security Administration (NHSA) has been conducting drug price negotiations for the inclusion of more drugs in the NRDL. Regarding this round of negotiation, Huang Huabo, Director of the Department of Medical and Pharmaceutical Service...
The Ministry of Public Health has nationwide responsibility for administration and enforcement of the law; various health administrative ... TX Hu,MJ Myers - 《Clinical Research & Regulatory Affairs》 被引量: 4发表: 2008年 New Evidence of the Impact of the National Drug Price Negotiation Policy ...